[Tumor markers in breast and endometrial cancer].
Basic studies developed from human cell lines or tissue biopsies have allowed to isolate monoclonal antibodies and complementary DNAs specific for tumoral antigens and rare proteins implicated in the control of cancer growth and invasiveness. Present clinical studies indicate that some molecular probes display a potential value as markers of tissue specificity, of hormone dependency or prognosis in breast and endometrial cancers.
Garcia
M
M
INSERM U 148, Unité d'Endocrinologie Cellulaire et Moléculaire, Montpellier.
Maudelonde
T
T
D000911:Antibodies, Monoclonal / Q000302:isolation & purification; D000951:Antigens, Neoplasm / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000032:analysis*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis*; D014594:Uterine Neoplasms / Q000032:analysis*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D011956:Receptors, Cell Surface
Marqueurs tumoraux des cancers du sein et de l'endomètre.